Gilead Sciences, Inc. has announced that the China Drug Administration (CDA) has approved Epclusa for the treatment of a...
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for bio...
Chinese e-commerce giant Alibaba Group Holding Ltd will inject some of its online pharmacy business into a listed unit i...
Shuwen Biotech Co. Ltd., an emerging leader in innovative diagnostic products and services has signed a partnership agre...
Luye Pharma Group recently announced their acquisition of AstraZeneca's core CNS products - Seroquel and Seroquel XR. As...
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, recently announced acquisition of Shan...
China's WuXi Biologics, a leading global open-access biologics technology platform recently announced pla...
Brii Bio, a startup committed to serving patients' needs and improving public health in China, recently announced its la...
Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences (NLFS) has announced the closing of Pivotal bioVen...
China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Ke...
Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Shanghai Pharmaceuticals Holding Co. Ltd., a leading p...
Grail, a Hong Kong-US oncology diagnostics company, recently announced a $300 million C financing. Ally Bridge Group led...
Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd., a multi-national leader in t...
China has created the world's first medical instrument that can induce, culture and screen stem cells automatically, ben...
Mason Group Holdings Limited announced the merger between its subsidiary Reproductive Healthcare and ...
Cuba and China have expanded their biotechnology cooperation with the signing of another memorandum of understanding for...
WuXi Biologics, a leading global open-access biologics technology platform company, offering end-to-end solutions for bi...
HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series...
